View all newsletters
Receive our newsletter - data, insights and analysis delivered to you
  1. Market Data
April 28, 2016

M&As this week: West Pharmaceuticals, DNA2.0

West Pharmaceuticals has invested in Nanopass technologies to access its expertise in intradermal drug delivery systems.

West Pharmaceuticals

West Pharmaceuticals has invested in Nanopass technologies to access its expertise in intradermal drug delivery systems.

The investment enables West Pharma and Nanopass to deliver new products to the market and also provides Nanopass with an opportunity to further enhance clinical development efforts and to introduce its micro-needle based devices for intradermal delivery of vaccines and drugs.

DNA2.0, a pharmaceutical company, has announced to acquire MIGS, a contract research organisation to accelerate its protein pharmaceutical research.

The asset purchase agreement enables DNA2.0 to gain a substantial hold of all of the assets of MIGS, as well as develop an unparalleled antibody production and engineering platform.


Image: The investment enables West Pharma and Nanopass to deliver new products to the market. Photo: courtesy of Eschweiler.

Related Companies

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. Key drug pipeline and competitive landscape changes based on the latest clinical activity, sent every Tuesday. Curated analysis and data-driven insights on clinical trials strategy and operations, sent every Thursday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU

Thank you for subscribing to Clinical Trials Arena